drugset / Trial / NCT01203592

Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes

NCT01203592

Phase 1 Completed 21 enrolled Mayo Clinic
NaSingle-groupOpen-labelTreatment

Summary

The study tests the notion that patients suffering from certain types of congenital myasthenic syndromes are benefitted by the use of Albuterol at doses used in clinical practice.

Timeline

Start
2010-09
Primary completion
2013-08
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Salbutamol Unknown 0.1 mg/kg Oral
Subject Salbutamol Unknown 2 mg Oral
Subject Salbutamol Unknown 4 mg Oral